Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Establishment, Validation, and Application of a New World Primate Model of Enterotoxigenic Escherichia coli Disease for Vaccine Development.

Rollenhagen JE, Jones F, Hall E, Maves R, Nunez G, Espinoza N, O'Dowd A, Prouty MG, Savarino SJ.

Infect Immun. 2019 Jan 24;87(2). pii: e00634-18. doi: 10.1128/IAI.00634-18. Print 2019 Feb.

2.

Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates.

Sincock SA, Hall ER, Woods CM, O'Dowd A, Poole ST, McVeigh AL, Nunez G, Espinoza N, Miller M, Savarino SJ.

Vaccine. 2016 Jan 4;34(2):284-291. doi: 10.1016/j.vaccine.2015.11.017. Epub 2015 Nov 18.

PMID:
26597148
3.

Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge.

Luiz WB, Rodrigues JF, Crabb JH, Savarino SJ, Ferreira LC.

Infect Immun. 2015 Dec;83(12):4555-64. doi: 10.1128/IAI.00858-15. Epub 2015 Sep 14.

4.

Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines.

Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA.

Clin Vaccine Immunol. 2011 Oct;18(10):1719-27. doi: 10.1128/CVI.05194-11. Epub 2011 Aug 18.

5.

Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.

Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA.

Clin Vaccine Immunol. 2015 Nov 18;23(1):55-64. doi: 10.1128/CVI.00617-15. Print 2016 Jan.

6.

Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.

Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM.

Vaccine. 2013 Feb 6;31(8):1163-70. doi: 10.1016/j.vaccine.2012.12.063. Epub 2013 Jan 7.

PMID:
23306362
8.

Immunization with the MipA, Skp, or ETEC_2479 Antigens Confers Protection against Enterotoxigenic E. coli Strains Expressing Different Colonization Factors in a Mouse Pulmonary Challenge Model.

Hays MP, Kumar A, Martinez-Becerra FJ, Hardwidge PR.

Front Cell Infect Microbiol. 2016 Dec 12;6:181. doi: 10.3389/fcimb.2016.00181. eCollection 2016.

9.

Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.

Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM.

Vaccine. 2013 May 7;31(20):2457-64. doi: 10.1016/j.vaccine.2013.03.027. Epub 2013 Mar 27.

10.

Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. coli-mediated diarrhea in pigs.

Takeyama N, Yuki Y, Tokuhara D, Oroku K, Mejima M, Kurokawa S, Kuroda M, Kodama T, Nagai S, Ueda S, Kiyono H.

Vaccine. 2015 Sep 22;33(39):5204-11. doi: 10.1016/j.vaccine.2015.07.074. Epub 2015 Aug 4.

PMID:
26254309
11.

Immunogenicity and protective efficacy of a single-dose live non-pathogenic Escherichia coli oral vaccine against F4-positive enterotoxigenic Escherichia coli challenge in pigs.

Fairbrother JM, Nadeau É, Bélanger L, Tremblay CL, Tremblay D, Brunelle M, Wolf R, Hellmann K, Hidalgo Á.

Vaccine. 2017 Jan 5;35(2):353-360. doi: 10.1016/j.vaccine.2016.11.045. Epub 2016 Dec 1.

12.

The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD.

Clin Vaccine Immunol. 2012 Dec;19(12):1921-31. doi: 10.1128/CVI.00364-12. Epub 2012 Oct 3.

15.

Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.

Chakraborty S, Harro C, DeNearing B, Brubaker J, Connor S, Maier N, Dally L, Flores J, Bourgeois AL, Walker R, Sack DA.

PLoS Negl Trop Dis. 2018 Apr 27;12(4):e0006442. doi: 10.1371/journal.pntd.0006442. eCollection 2018 Apr.

16.

Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection.

Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, Schiller ZA, Thomas WD Jr, Barry EM, Cavacini LA, Klempner MS, Wang Y.

Infect Immun. 2018 Jul 23;86(8). pii: e00355-18. doi: 10.1128/IAI.00355-18. Print 2018 Aug. Erratum in: Infect Immun. 2018 Nov 20;86(12):.

17.

Evaluation of transcutaneous immunization as a delivery route for an enterotoxigenic E. coli adhesin-based vaccine with CfaE, the colonization factor antigen 1 (CFA/I) tip adhesin.

Rollenhagen JE, Woods CM, O'Dowd A, Poole ST, Tian JH, Guebre-Xabier M, Ellingsworth L, Prouty MG, Glenn G, Savarino SJ.

Vaccine. 2019 Sep 30;37(42):6134-6138. doi: 10.1016/j.vaccine.2019.08.057. Epub 2019 Sep 3.

18.

Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTaN12S-dmLT protect against STa+ enterotoxigenic Escherichia coli (ETEC) diarrhea in a pig model.

Nandre RM, Duan Q, Wang Y, Zhang W.

Vaccine. 2017 Jan 23;35(4):552-556. doi: 10.1016/j.vaccine.2016.12.021. Epub 2016 Dec 22.

20.

Significance of Enterotoxigenic Escherichia coli (ETEC) Heat-Labile Toxin (LT) Enzymatic Subunit Epitopes in LT Enterotoxicity and Immunogenicity.

Huang J, Duan Q, Zhang W.

Appl Environ Microbiol. 2018 Jul 17;84(15). pii: e00849-18. doi: 10.1128/AEM.00849-18. Print 2018 Aug 1.

Supplemental Content

Support Center